Generated by AI
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for Alzheimer’s disease. The company’s lead program centers on sabirnetug (ACU193), an investigational immunotherapy designed to selectively target toxic soluble amyloid beta oligomers, which are believed to contribute to Alzheimer’s pathology. Acumen’s work is aimed at disease-modifying treatment approaches rather than symptom management, with its research and clinical programs concentrated on early symptomatic and mild Alzheimer’s disease. Headquartered in Newton, Massachusetts, Acumen Pharmaceuticals operates within the neuroscience and biotechnology sectors, where it plays a specialized role in advancing antibody-based therapies and diagnostics for neurodegenerative disease.
Website1210-1220 Washington St.
Newton, MA, 02465
United States
The latest articles about ABOS.
Acumen Pharmaceuticals' lead Alzheimer's drug sabirnetug failed to show clinical efficacy in the ALTITUDE-AD trial. See why ABOS stock is downgraded to a sell.
CRYSTAL LAKE, Ill., September 14, 2026--Aptar and Massachusetts General Hospital Collaborate on Platform to Establish Predictive, Data-Driven Model for Advancing Nose-to-Brain Drug Delivery
Summary of Nov 3's posts. Generated by AI.
Summary of Oct 30's posts. Generated by AI.
Summary of Jul 26's posts. Generated by AI.
Summary of Nov 2's posts. Generated by AI.
Investors talking about ABOS also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.